Bloomberg Talks Pfizer CEO Albert Bourla Talks Weight Loss Drugs
5 snips
Jan 12, 2026 Albert Bourla, the Chairman and CEO of Pfizer, shares insights on the company's innovative weight-loss drugs. He emphasizes their aim for superior results and discusses the promising MetSera acquisition, designed for enhanced weight loss with a unique dosing approach. Bourla also expresses satisfaction with Pfizer’s growth trajectory, forecasting impressive sales, while highlighting their commitment to reinvesting in crucial R&D areas like oncology and obesity. His thoughts on engaging with policymakers offer a glimpse into the interplay between business and government in the pharmaceutical sector.
AI Snips
Chapters
Transcript
Episode notes
Catalyst-Rich Year To Reignite Growth
- Pfizer expects multiple near-term clinical catalysts across obesity, oncology and vaccines that should engage investors.
- Albert Bourla says these readouts and phase 3 starts will drive the company's growth trajectory before 2028.
High-Impact Readouts Span Multiple Therapies
- Specific readouts mentioned include monthly-dosing data, GLP-1 plus amylin combos, a myeloma study (L-rexio) and a Lyme vaccine.
- Bourla highlights that successful trials could expand indications and market populations significantly.
Monthly Dosing As A Major Differentiator
- Metsera's monthly dosing and amylin-plus-GLP-1 combo aim to deliver superior weight loss and tolerability.
- Bourla frames monthly dosing as a major patient-experience and cost advantage over current GLP-1s.